A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
| Status: | Completed |
|---|---|
| Conditions: | Acne, Acne, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 11/21/2018 |
| Start Date: | October 2015 |
| End Date: | April 2016 |
A Double-blind, Double-dummy, Randomized, 4-period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared With Placebo and Moxifloxacin in Subjects With Acne Vulgaris: A Thorough ECG STudy
A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects
of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a
Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a
Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
A Double-Blind, Double-Dummy, Randomized, 4-Period, Crossover Study to Define the ECG Effects
of SB204 Using a Clinical and a Supratherapeutic Dose Compared with Placebo and Moxifloxacin
(a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
of SB204 Using a Clinical and a Supratherapeutic Dose Compared with Placebo and Moxifloxacin
(a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
Inclusion Criteria:
- Moderate to severe acne
- 20 inflammatory and 25 non-inflammatory acne lesions
Exclusion Criteria:
- Pregnant, trying to become pregnant, or nursing
- Known allergy to any component of the topical SB204 formulation
We found this trial at
1
site
Click here to add this to my saved trials
